VEGFA and neoplasm: For example, bevacizumab (an anti-VEGF therapy) combined with the CCL2 inhibitor mNOX-E36 decreased the recruitment of TAMs and angiogenesis, resulting in decreased tumor volume in a rat glioblastoma multiforme model [180].